Market Overview

Cara Therapeutics Rallies On Positive Opioid Receptor Agonist Trial Results

Share:
Cara Therapeutics Rallies On Positive Opioid Receptor Agonist Trial Results

Cara Therapeutics Inc (NASDAQ: CARA) popped more than 32 percent Wednesday morning after management reported positive top-line data for a drug candidate. 

What Happened

A Phase 2/3 trial of intravenous CR845 in abdominal surgery patients achieved primary endpoints for pain relief and secondary endpoints for nausea and vomiting reduction.

Why It’s Important

The drug could be the first approved kappa opioid receptor agonist, which selectively targets such receptors to mitigate potentially addictive properties.

"As there continues to be a critical need for new post-surgical analgesics like I.V. CR845 that lack abuse potential and traditional mu opioid side effects, we will be assessing all options, including discussions with regulators, as to how to best move this program forward,” Derek Chalmers, Cara's president and CEO, said in a press release.

What’s Next

Cara will present the full trial results at a future conference.

The stock was rallyin 29.56 percent premarket Wednesday. 

Related Links:

Cara Therapeutics Shares Jump On Licensing Deal For Pruritis Treatment

Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results

Posted-In: News Health Care FDA General Best of Benzinga

 

Related Articles (CARA)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Conagra's Acquisition Of Pinnacle Foods: What You Need To Know

Benzinga Pro's 5 Stocks To Watch Today